Beigene Ltd
ONC269.630USD
-6.900-2.50%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
26.72BValor de mercado
PerdaP/L TTM
Mais detalhes de Beigene Ltd Empresa
BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.
Informações da empresa
Código da empresaONC
Nome da EmpresaBeigene Ltd
Data de listagem- -
Fundado em2010
CEOMr. John Victor Oyler
Número de funcionários11000
Tipo de títulosOrdinary Share
Fim do ano fiscal- -
Endereçoc/o Mourant Governance Services (Cayman)
CidadeGRAND CAYMAN
Bolsa de valoresThe Toronto Stock Exchange
PaísCayman Islands
Código postalKY1-1108
Telefone13459494123
Sitehttps://www.beigene.com/
Código da empresaONC
Data de listagem- -
Fundado em2010
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Distribuição de ações
Atualizado em: ter, 3 de jun
Atualizado em: ter, 3 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Investidores
Investidores
Proporção
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Tipos de investidores
Investidores
Proporção
Investment Advisor
21.70%
Corporation
17.31%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.86%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.68%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
559
66.79M
67.51%
+1.06M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: seg, 2 de jun
Atualizado em: seg, 2 de jun
Nome
Proporção
First Trust NYSE Arca Biotechnology Index Fund
3.51%
Innovator IBD 50 Fund ETF
3.07%
Tema Oncology ETF
2.94%
Virtus LifeSci Biotech Products ETF
2.51%
VanEck Biotech ETF
2.23%
Global X Aging Population ETF
2.05%
iShares Health Innovation Active ETF
1.51%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.17%
ProShares Ultra Nasdaq Biotechnology
1.17%
Ver Mais
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.51%
Innovator IBD 50 Fund ETF
Proporção3.07%
Tema Oncology ETF
Proporção2.94%
Virtus LifeSci Biotech Products ETF
Proporção2.51%
VanEck Biotech ETF
Proporção2.23%
Global X Aging Population ETF
Proporção2.05%
iShares Health Innovation Active ETF
Proporção1.51%
iShares Biotechnology ETF
Proporção1.42%
Invesco Nasdaq Biotechnology ETF
Proporção1.17%
ProShares Ultra Nasdaq Biotechnology
Proporção1.17%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
